CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry

Original Research2016 Dec;9(12).

JOURNAL:Circ Cardiovasc Interv. Article Link

Clinical Impact of Suboptimal Stenting and Residual Intrastent Plaque/Thrombus Protrusion in Patients With Acute Coronary Syndrome: The CLI-OPCI ACS Substudy (Centro per la Lotta Contro L'Infarto-Optimization of Percutaneous Coronary Intervention in Acute Coronary Syndrome)

Prati F, Romagnoli E, Mintz GS et al. Keywords: acute coronary syndrome; percutaneous coronary intervention; prognosis; registries; stents

ABSTRACT